FilingReader Intelligence
Huahai Pharma receives approval, advances clinical trials
May 26, 2025 at 12:16 PM UTC•By FilingReader AI
Zhejiang Huahai Pharmaceutical (SSE:600521) announced that it has received a drug registration certificate from the National Medical Products Administration for its Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets. The tablets, used to improve blood sugar control in adults with type 2 diabetes, come in multiple strengths. According to market predictions, the drug could generate CNY 195 million in domestic sales in 2024.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
News Alerts
Get instant email alerts when Zhejiang Huahai Pharmaceutical publishes news
Free account required • Unsubscribe anytime